Navigation Links
EORTC presents European solution for effective cancer drug development
Date:7/1/2014

Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, not to mention issues concerning R&D productivity. There needs to be a better way to identify new candidate drugs. There needs to be a new drug development pathway that is compatible with research aimed at understanding the biology of a cancer and simultaneously able to support the design and conduct of subsequent confirmatory trials, but building and maintaining such a drug development pathway is beyond the ability of individual organizations or companies. It has been argued that new forms of partnership as well as an integrated model of cancer research are needed. Now, in a paper published in Nature Reviews Clinical Oncology, the EORTC describes how collaborative molecular screening platforms could help serve these needs.

Collaborative molecular screening platforms offer a high quality integrated infrastructure for efficient screening of patients with cancer for specific molecular alterations. These identified alterations will define target populations for early trials with novel targeted agents. Pharmaceutical industry partners would be in a position to propose candidate drugs for clinical trials which could be plugged into the platform. Patients fulfilling the inclusion criteria for one or more trials would be notified by their physician and given the option of participating.

Dr. Denis Lacombe, EORTC Director and lead author of this paper says, "Collaborative molecular screening platforms will offer patients efficient access to new therapeutic agents. Clinical research will be turned on its head. Instead of designing trials which must find patients for a particular drug, the question will become which drug should be given to a particular subset of patients with an identified molecular alteration."

Collaborative molecular screening platforms are a winning proposition for all cancer drug development stakeholders. As information-sharing platforms they enable us to learn from our failures. They accommodate the integration of information from continuous risk assessments and pave the way for an adaptive licensing strategy. Importantly, they enhance the expertise of the constituent partners by combining their efforts within a cost-sharing model and could very well be the realization of personalized medicine.


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC to present cancer research results at ASCO 2014
2. NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
3. EORTC and SIOG update expert opinion on management of elderly patients with NSCLC
4. EORTC study shows value of HRQOL assessment in small cell lung cancer
5. Joint EORTC-ESTRO session to focus on current developments in soft tissue sarcoma treatment
6. EORTC Cancer in the Elderly Task Force investigates appropriate treatment for elderly patients
7. EORTC head & neck cancer trial shows assessing HRQOL is valuable to both patients and their doctors
8. Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
9. Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study
10. EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
11. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... CURE Media Group, the nation’s leading digital and print media ... Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael ... Media Group is honored to team up with Upstage Lung Cancer in order to ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ... and patients about the safety issues related to dental restorations. According to the American ... projected to reach $6.4 billion in 2018 with more than 30 million Americans missing ...
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Bodycad announced it has been ... accuracy, reproducibility and speed for 3D constructs via ... bone orthopaedic applications. These patents are critical to ... restorations based on each patient,s distinct anatomy. ... harnesses the world,s first suite of orthopaedic CAD/CAM ...
(Date:12/8/2016)... 2016  Pennsylvania Physician General Dr. Rachel ... Programs Gary Tennis released safe prescribing ... benzodiazepines, developed with the help of a task ... are frequently prescribed for anxiety or insomnia," said ... opioid pain medications, benzodiazepines pose a significant risk ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: